Klinická farmakologie a farmacie – 3/2021

www.klinickafarmakologie.cz / Klin Farmakol Farm 2021; 35(3): 61–69 / KLINICKÁ FARMAKOLOGIE A FARMACIE 69 HLAVNÍ TÉMA Současné trendy v léčbě akutní myeloidní leukemie – od indukční chemoterapie „7+3“ po cílenou léčbu zvou je nejen výběr vhodných léků, ale i ma‑ nagement nových nežádoucích účinků. Další, neméně palčivou problematikou, je i chybějící úhrada u některých léků. Navzdory prvotním slibným výsledkům cílené terapie se zdá být ne‑ pravděpodobné, že zasažení jediné patologické signální dráhy by mohlo vést k dlouhodobému vyléčení. Odhalení molekulárních mechanismů leukemogeneze a rezistence může přispět k lep‑ šímu pochopení signálních drah a vývoji účinnější terapie. Další intenzivní výzkuma vývoj nových lé‑ ků nadále probíhá, aplikace jejich výsledků do kli‑ nické praxe je tak příslibempro zlepšení prognó‑ zy a dlouhodobých léčebných výsledků AML. Práce byla podpořena grantem IGA_ LF_2021_001 a MZ ČR – RVO (FNOL, 00098892). LITERATURA 1. Kouchkovsky ID, Abdul‑Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J 2016; 6(7): e441. 2. Szotkowski T. Akutní myeloidní leukemie. In: Indrák K et al. Hematologie a transfuzní lékařství. Triton 2014: 260–265. 3. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemie. N Engl J Med 2015; 373: 1136–1152. 4. Döhner H, Estey E, Grimwade D et al. Diagnosis and management of AML in adults: 2017 ELN recommendati‑ ons from an international expert panel. Blood 2017; 129 (4): 424–447. 5. Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011; 29(5): 487–494. 6. Tawfik B, Pardee TS, Isom S et al. Comorbidity, age, and mor‑ tality among adults treated intensively for acute myeloid le‑ ukemia (AML). J Geriatr Oncol 2016; 7(1): 24–31. 7. Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refracto‑ ry and early relapsed acute myeloid leukemia. Blood 2015; 126: 319–327. 8. Grimwade D, Hills RK, Moorman AV et al. Refinement of cy‑ togenetic classification in acute myeloid leukemia: determi‑ nation of prognostic significance of rare recurring chromoso‑ mal abnormalities among 5876 younger adult patients trea‑ ted in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354–365. 9. Bloomfield CD, Lawrence D, Byrd JC et al. Frequency of prolonged remission duration after high‑dose cytarabine intensification in acute myeloid leukemia varies by cytoge‑ netic subtype. Cancer Res 1998; 58: 4173–4179. 10. Weick JK, Kopecky KJ, Appelbaum FR et al. A randomi‑ zed investigation of high‑dose versus standard‑dose cytosi‑ ne arabinoside with daunorubicin in patients with previou‑ sly untreated acute myeloid leukemia: a Southwest oncolo‑ gy group study. Blood 1996; 88(8): 2841–2851. 11. Molica M, Breccia M, Foa R, Jabbour E, Kadia TM. Mainte‑ nance therapy in AML: The past, the present and the future. Am J Hematol 2019; 94(11): 1254–1265. 12. Stone RM, Mandrekar S, Sanford BL et al. The multi‑kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high‑dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18–60 with FLT3 mutations (muts): An international prospective randomized (rand) P‑controlled double‑blind trial (CALGB 10603/RATIFY [Alliance]). Blood 2015; 126: 6. 13. SÚKL: Midostaurin–Souhrn údajů o přípravku [cit. 24. 8. 2021]. Dostupný na: https://www.ema.europa.eu/en/ documents/product‑information/rydapt‑epar‑product­ ‑information_cs.pdf a https://www.sukl.cz/modules/medi‑ cation/detail.php?code=0222463 & tab=prices 14. Burnett AK, Milligan D, Prentice AG et al. A comparison of low‑dose cytarabine and hydroxyurea with or without all­ ‑trans retinoic acid for acute myeloid leukemia and high‑risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007; 109(6): 1114–1124. 15. Heiblig M, Elhamri M, Tigaud I et al. Treatment with low­ ‑dose cytarabine in elderly patients (age 70 years or older) with acute myeloid leukemia: A single institution experience. Mediterr J Hematol Infect Dis 2016; 8(1): e2016009. 16. Fernandez HF, Sun Z, Yao X et al. Anthracycline dose in‑ tensification in acute myeloid leukemia. N Engl J Med 2009; 361: 1249–1259. 17. Burnett AK, Russell NH, Hills RK et al. Optimization of che‑ motherapy for younger patients with acute myeloid leuke‑ mia: results of the medical research council AML15 trial. J Clin Oncol 2013; 31(27): 3360–3368. 18. The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059–2074. 19. Saultz JN, Garzon R. Acute myeloid leukemia: A concise review. J Clin Med 2016; 5: 33. 20. Campos L, Rouault JP, Sabido O et al. High expressi‑ on of bcl-2 protein in acute myeloid leukemia cells is asso‑ ciated with poor response to chemotherapy. Blood 1993; 81(11): 3091–3096. 21. Konopleva M, Pollyea DA, Potluri J et al. Efficacy and bio‑ logical correlates of response in a phase II study of venetoc‑ lax monotherapy in patients with acute myelogenous leu‑ kemia. Cancer Discov 2016; 6(10): 1106–1117. 22. DiNardo CD, Jonas BA, Pullarkat V et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med 2020; 383: 617–629. 23. Wei AH, Montesinos P, Ivanov V et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemothe‑ rapy: a phase 3 randomized placebo‑controlled trial. Blood 2020; 135(24): 2137–2145. 24. DiNardo CD, Pratz K, Pullarkat V et al. Venetoclax com‑ bined with decitabine or azacitidine in treatment‑naive, elderly patients with acute myeloid leukemia. Blood 2018; 133(1): 7–17. 25. Tiong IS, Savona M, Lee S et al. Venetoclax combined with low‑dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II stu‑ dy. J Clin Oncol 2019; 37(15): 1277–1284. 26. Chua CC, Roberts AW, Reynolds J et al. Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CA‑ VEAT): a phase Ib dose‑escalation study of venetoclax com‑ bined with modified intensive chemotherapy. J Clin Oncol 2020; 35: 3506–3517. 27. Rücker FG, Schlenk RF, Bullinger L et al. TP53 alterations in acute myeloid leukemia with complex karyotype corre‑ late with specific copy number alterations, monosomal ka‑ ryotype, and dismal outcome. Blood 2012; 119(9): 2114–2121. 28. Sallman DA, DeZern AE, Garcia‑Manero G et al. Pha‑ se 2 results of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML). Blood 2019; 134(Supplement 1): 676–676. 29. Daver N, Wei AH, Pollyea DA, Fathi AT, Vyas P, DiNardo CD. New directions for emerging therapies in acute myeloid leu‑ kemia: the next chapter. Blood Cancer Journal 2020; 10: 107. 30. Chao MP, Takimoto CH, Feng DD et al. Therapeutic targe‑ ting of the macrophage immune checkpoint CD47 in mye‑ loid malignancies. Front Oncol 2020; 9: 1380. 31. Dombret H, Seymour JF, Butrym A et al. International pha‑ se 3 study of azacitidine vs conventional care regimens in ol‑ der patients with newly diagnosed AML with > 30 % blasts. Blood 2015; 126(3): 291–299. 32. Fenaux P, Mufti GJ, Hellström‑Lindberg E. Azacitidine pro‑ longs overall survival compared with conventional care regi‑ mens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28(4): 562–569. 33. Wei AH, Döhner H, Pocock Ch et al. Oral Azacitidine Main‑ tenance Therapy for Acute Myeloid Leukemia in First Remi‑ ssion. N Engl J Med 2020; 383: 526–253. 34. SÚKL: Venetoclax – Souhrn údajů o přípravku [cit. 24. 8. 2021]. Dostupný na: https://www.ema.europa.eu/en/ documents/product‑information/venclyxto‑epar‑product­ ‑information_cs.pdf a https://www.sukl.cz/modules/medi‑ cation/detail.php?code=0219166 & tab=prices 35. SÚKL: Azacitidin–Souhrn údajů o přípravku [cit. 24. 8. 2021]. Dostupný na: https://www.ema.europa.eu/en/documents/ product‑information/vidaza‑epar‑product‑information_ cs.pdf a https://www.sukl.cz/modules/medication/detail. php?code=0500947 & tab=prices 36. Sievers EL, Larson RA, Stadtmauer EA et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-po‑ sitive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19(13): 3244–3254. 37. Petersdorf SH, Kopecky KJ, Slovak M et al. A phase 3 stu‑ dy of gemtuzumab ozogamicin during induction and post‑ consolidation therapy in younger patients with acute mye‑ loid leukemia. Blood 2013; 121(24): 4854–4860. 38. Rowe JM, Löwenberg B. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood 2013; 121: 4838–4841. 39. Castaigne S, Pautas C, Terré Ch et al. Effect of gemtuzu‑ mab ozogamicin on survival of adult patients with de‑novo acute myeloid leukaemia (ALFA-0701): a randomised, open­ ‑label, phase 3 study. Lancet 2012; 379(9825): 1508–1516. 40. EMA: Mylotarg [cit. 24. 8. 2021]. Dostupný na: https://www. ema.europa.eu/en/medicines/human/EPAR/mylotarg-0 41. SÚKL: Mylotarg–Souhrn údajů o přípravku [cit. 24. 8. 2021]. Dostupný na: https://www.ema.europa.eu/en/documents/ product‑information/mylotarg‑epar‑product‑information_ cs.pdf a https://www.sukl.cz/modules/medication/detail. php?code=0222910 & tab=prices 42. Gazdová J, Dvořáková D, Ježíšková I, Rázga F, Jurček T, Mayer J. Úloha FLT3 mutací v patogenezi akutní myeloidní leukemie. Transfuze Hematol. dnes 2009; 4: 229–236. 43. Perl AE., Martinelli G, Cortes JE et al. Gilteritinib or Che‑ motherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med 2019; 381: 1728–1740. 44. SÚKL: Xospata – Souhrn údajů o přípravku [cit. 24. 8. 2021]. Dostupný na: https://www.ema.europa.eu/en/documents/ product‑information/xospata‑epar‑product‑information_ cs.pdf a https://www.sukl.cz/modules/medication/detail. php?code=0238673 & tab=prices 45. Sanz MA, Iacoboni G, Montesinos P, Venditti A. Emer‑ ging strategies for the treatment of older patients with acu‑ te myeloid leukemia. Ann Hematol 2016; 95(10): 1583–1593.